Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
41
EVO Quote, Financials, Valuation and Earnings
Last price:
$4.2600
Seasonality move
:
-0.65%
Day range:
$4.1621 - $4.2400
52-week range:
$2.8400 - $5.6405
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.77x
P/B ratio:
1.52x
Volume:
35K
Avg. volume:
101.4K
1-year change:
-11.72%
Market cap:
$1.5B
Revenue:
$862.6M
EPS (TTM):
-$0.63
Analysts' Opinion
-
Consensus RatingEvotec SE has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.1171, Evotec SE has an estimated upside of 44.98% from its current price of $4.2200.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.1447 representing 100% downside risk from its current price of $4.2200.
Fair Value
-
According to the consensus of 2 analysts, Evotec SE has 44.98% upside to fair value with a price target of $6.1171 per share.
EVO vs. S&P 500
-
Over the past 5 trading days, Evotec SE has overperformed the S&P 500 by 1.62% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Evotec SE does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evotec SE revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Evotec SE reported revenues of $210.4M.
Earnings Growth
-
Evotec SE has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Evotec SE reported earnings per share of -$0.09.
Enterprise value:
1.2B
EV / Invested capital:
--
Price / LTM sales:
1.77x
EV / EBIT:
--
EV / Revenue:
1.37x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-14.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$114.8M
Return On Assets:
-10.26%
Net Income Margin (TTM):
-26.32%
Return On Equity:
-20.84%
Return On Invested Capital:
-14.69%
Operating Margin:
-9.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $834.1M | $842.9M | $845.7M | $226.7M | $210.4M | |
| Gross Profit | $203M | $170M | $114.8M | $37.8M | $28.6M | |
| Operating Income | $34.3M | -$62.5M | -$87.1M | -$19.8M | -$20.9M | |
| EBITDA | -$82.2M | -$96.9M | -$200.1M | -$26.2M | -$28.9M | |
| Diluted EPS | -$0.34 | -$0.28 | -$0.63 | -$0.07 | -$0.09 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $797.6M | $1.2B | -- | $892.2M | $783.5M | |
| Total Assets | $1.9B | $2.4B | -- | $2.4B | $2.1B | |
| Current Liabilities | $280.9M | $379.1M | -- | $478.4M | $386.3M | |
| Total Liabilities | $923.4M | $976.8M | -- | $1.2B | $1.1B | |
| Total Equity | $929.7M | $1.5B | -- | $1.2B | $987.2M | |
| Total Debt | $431.9M | $404.3M | -- | $677.7M | $65.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $146.3M | -$13.6M | $38.6M | -$52.3M | -$33.5M | |
| Cash From Investing | -$332.9M | -$43M | -$66.2M | -$33.6M | -$22.7M | |
| Cash From Financing | -$59.1M | $75.3M | -$131.1M | -$6.4M | $37.3M | |
| Free Cash Flow | -$43.1M | -$248.1M | -$80.6M | -$99.3M | -$56.4M | |
EVO
Sector
Market Cap
$1.5B
$34.4M
Price % of 52-Week High
74.82%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-11.72%
-37.36%
Beta (5-Year)
1.658
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.1650
200-day SMA
Buy
Level
$4.0683
Bollinger Bands (100)
Buy
Level
3.5133 - 4.2933
Chaikin Money Flow
Sell
Level
-54.3K
20-day SMA
Buy
Level
$4.1240
Relative Strength Index (RSI14)
Buy
Level
53.7444
ADX Line
Buy
Level
19.609
Williams %R
Neutral
Level
-41.8141
50-day SMA
Buy
Level
$4.1171
MACD (12, 26)
Buy
Level
1.1383
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
122.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7131)
Sell
CA Score
(Annual)
Level (-0.7226)
Buy
Beneish M-Score
(Annual)
Level (-2.6044)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.2906)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Stock Forecast FAQ
In the current month, EVO has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The EVO average analyst price target in the past 3 months is $6.1171.
-
Where Will Evotec SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evotec SE share price will rise to $6.1171 per share over the next 12 months.
-
What Do Analysts Say About Evotec SE?
Analysts are divided on their view about Evotec SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evotec SE is a Sell and believe this share price will drop from its current level to $3.1447.
-
What Is Evotec SE's Price Target?
The price target for Evotec SE over the next 1-year time period is forecast to be $6.1171 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is EVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evotec SE is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of EVO?
You can purchase shares of Evotec SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evotec SE shares.
-
What Is The Evotec SE Share Price Today?
Evotec SE was last trading at $4.2600 per share. This represents the most recent stock quote for Evotec SE. Yesterday, Evotec SE closed at $4.2200 per share.
-
How To Buy Evotec SE Stock Online?
In order to purchase Evotec SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 3.58% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.66% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 8.31% over the past day.
